349) Results obtained showed that aberrant methylation of p15 and p16 genes were detected in 64.29 and 50% of ovarian cancer patients, while E-cadherin hypermethylation was detected in 78.57% of ovarian cancer patients. |
PMID:23572389 DOI:10.1177/0748233713484657 |
2015 Toxicology and industrial health |
* Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer. |
- Both p16 and p15 proteins are inhibitors of cyclin-dependent kinases that prevent the cell going through the G1/S phase transaction. E-cadherin is a transmembrane glycoprotein that mediates calcium-dependent interactions between adjacent epithelial cells. Two groups of patients were selected: the first group suffered from epithelial serous ovarian tumors and the second group suffered from benign ovarian lesions; ovarian tissue samples from all the subjects (benign and malignant) were subjected to methylation-specific polymerase chain reaction for methylated and unmethylated alleles of the genes (E-cadherin, p15, and p16). Results obtained showed that aberrant methylation of p15 and p16 genes were detected in 64.29 and 50% of ovarian cancer patients, while E-cadherin hypermethylation was detected in 78.57% of ovarian cancer patients. Methylation of E-cadherin was significantly correlated with different stage of disease (p < 0.05). It was found that the risk of E-cadherin hypermethylation was 1.347-fold, while risk of p15 hypermethylation was 1.543-fold and p16 was 1.2-fold among patients with ovarian cancer than that among patients with benign ovarian lesions. In conclusion, Dysfunction of the cell cycle and/or the cell-cell adhesion molecule plays a role in the pathogenesis of ovarian cancer and that the analysis of the methylation of p15 and E-cadherin genes can provide clinically important evidence on which to base the treatment. |
(1)65 *null* | (14)6 therapy | (27)3 of | (40)2 epigenetics |
(2)48 cells | (15)6 tissues | (28)3 patients, | (41)2 growth |
(3)33 and | (16)5 cells, | (29)3 research | (42)2 initiation |
(4)32 cell | (17)5 progression | (30)3 was | (43)2 prevention |
(5)23 patients | (18)5 registries | (31)2 (GC) | (44)2 registry |
(6)15 in | (19)4 at | (32)2 biology | (45)2 study |
(7)14 is | (20)4 deaths | (33)2 but | (46)2 susceptibility |
(8)12 risk | (21)4 has | (34)2 can | (47)2 than |
(9)12 screening | (22)4 mortality | (35)2 care | (48)2 treated |
(10)12 stem | (23)3 (CRC) | (36)2 development | (49)2 treatment |
(11)9 survivors | (24)3 as | (37)2 diagnostic | (50)2 using |
(12)7 with | (25)3 cases | (38)2 drug | |
(13)6 are | (26)3 metabolism | (39)2 drugs |
add keyword